ABCL — AbCellera Biologics Inc. stock price, charts and financials

Latest market price

6.09

+0.26+4.46%

Overview Short InterestFilings

ABCLQT58AbCellera Biologics Inc.·NASDAQ

Overview Short InterestFilings

6.09+4.46%

Earnings

Up 4.5% — Reported earnings — EPS beat by 18%, revenue beat by 54%.

High confidence

Loading chart...

Signal & projected range

Short-squeeze setupHistorical pattern — not a prediction

Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)

Horizon

Unlock the projected rangeSee where this setup landed historically — with Premium.

Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →

OCUL+2.26%$8.59 MESO+2.28%$14.80 AUPH+2.47%$14.93 TYRA+1.53%$32.53 URGN+3.45%$39.92 IOVA+0.93%$4.36 STOK+7.14%$31.67 TSHA+7.27%$6.20

Snapshot

Index	-	P/E	-	EPS (ttm)	-0.48	Insider Own	-	Shs Outstand	305.38M	Perf Week	15.12%

Market Cap	1.86B	Forward P/E	-	EPS next Y	-0.64	Insider Trans	0.14%	Shs Float	205.09M	Perf Month	-22.62%

Enterprise Value	1.49B	PEG	-	EPS next Q	-	Inst Own	-	Short Float	22.00%	Perf Quarter	32.68%

Income	-144.00M	P/S	23.54	EPS this Y	-22.92%	Inst Trans	-	Short Ratio	5.65	Perf Half Y	74.00%

Sales	79.00M	P/B	1.98	EPS next Y	-9.23%	ROA	-11.01%	Short Interest	45.11M	Perf YTD	78.07%

Book/sh	3.07	P/C	3.68	EPS next 5Y	-	ROE	-14.86%	52W High	8.44 -27.84%	Perf Year	43.63%

Cash/sh	1.65	P/FCF	-	EPS past 3/5Y	-	ROIC	-13.84%	52W Low	2.75 121.45%	Perf 3Y	-20.81%

Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-46.32% -20.28%	Gross Margin	79.07%	Volatility	6.57% 7.57%	Perf 5Y	-58.99%

Dividend TTM	-	EV/Sales	18.84	EPS Y/Y TTM	12.73%	Oper. Margin	-267.61%	ATR (14)	0.47	Perf 10Y	-

Dividend Ex-Date	-	Quick Ratio	13.89	Sales Y/Y TTM	172.41%	Profit Margin	-181.75%	RSI (14)	51.23	Recom	2.09

Dividend Gr. 3/5Y	-	Current Ratio	14.05	EPS Q/Q	6.67%	SMA20	0.21%	Beta	1.16	Target Price	7.50

Payout	0.00%	Debt/Eq	0.14	Sales Q/Q	100.00%	SMA50	-0.49%	Rel Volume	0.53	Prev Close	5.83

Employees	562	LT Debt/Eq	0.14	Earnings	Aug 05	SMA200	35.85%	Avg Volume	7.44M	Price	6.09

IPO Date	Dec 11, 2020	Option/Short	Yes / Yes	EPS/Sales Surpr.	18.33% 53.63%	Net Debt/EBITDA	-0.40	Volume	3,941,683	Change	4.46%

Analyst Ratings

Date	Action	Analyst	Rating	Target
Jul-07-26	Upgrade	Benchmark	Hold → Buy
May-12-26	Reiterated	Stifel Nicolaus		$7.00 → $8.00
May-05-26	Initiated	Cantor Fitzgerald	Overweight	$7.00
Nov-07-25	Downgrade	Leerink Partners	Outperform → Market Perform
Nov-05-24	Reiterated	BMO Capital	Outperform	$5.00
Aug-23-24	Reiterated	KeyBanc	Overweight	$7.00 → $5.00
Aug-20-24	Downgrade	Benchmark	Buy → Hold
May-08-24	Reiterated	Keybanc	Overweight	$7.00
Feb-22-24	Upgrade	Benchmark	Hold → Buy
Jan-06-23	Reiterated	Leerink Partners		$18

Latest News

Jul-29-26

Jul-29-2607:06AM

Shares of several healthcare companies are trading higher as the market rebounds from coronavirus-related selloffs.Benzinga

07:00AM

AbCellera Announces Collaboration with Vertex to Discover Multispecific T-Cell Engagers for Autoimmune Diseases and Other Conditionsbusinesswire.com

Jul-23-26

Jul-23-2603:15PM

Playing The Biotech Breakout With Insidersseekingalpha.com

09:05AM

An AI Biotech Just Reported a 46% Revenue Jump and Its First Recurring Platform Contracts, as Its Pivot Starts Showing Up in the Numbersprnewswire.com

Jul-21-26

Jul-21-2601:26PM

Tracking Baker Brothers Portfolio: Q1 2026 UpdateSeekingAlpha

Jul-07-26

Jul-07-2604:05PM

AbCellera to Report Second Quarter 2026 Financial Results on August 5, 2026businesswire.com

01:01PM

Are You Looking for a Top Momentum Pick? Why AbCellera Biologics Inc. (ABCL) is a Great Choicezacks.com

07:50AM

Benchmark Upgrades AbCellera Biologics to Buy, Announces $11 Price TargetBenzinga

Jul-06-26

Jul-06-2609:00AM

AbCellera Appoints Dr. Lynn Seely to its Board of Directorsbusinesswire.com

Jul-03-26

Jul-03-2610:41AM

Is ABCELLERA BIOLG (ABCL) Stock Outpacing Its Medical Peers This Year?zacks.com

Jun-29-26

Jun-29-2605:20PM

Biotech Is The Rate Cut Trade In DisguiseSeekingAlpha

Jun-17-26

Jun-17-2612:54PM

Jazz Pharmaceuticals Gains Oncology Firepower Through AbCellera CollaborationBenzinga

07:11AM

Jazz Pharma And AbCellera Announce Preclinical Research Collaboration, Option And License Agreement To Discover, Develop Next-Gen T-Cell Engaging Multispecific AntibodiesBenzinga

06:33AM

AbCellera: An AI-Era Antibody Platform Trading For Little More Than Its CashSeekingAlpha

Company

AbCellera Biologics Inc. specializes in pioneering an advanced platform for the discovery of antibodies. This comprehensive, AI-driven system meticulously explores and analyzes natural immune systems to identify antibodies suitable for the creation of new pharmaceutical drugs. As of December 31, 2021, the company had cultivated 156 discovery programs, ranging from completed to in-progress or under contract, in partnership with 36 entities. Notably, AbCellera maintains a crucial research collaboration and license agreement with Eli Lilly and Company. Founded in 2012, the firm is headquartered in Vancouver, Canada.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements

DataTimeframe

Line Item (USD, M)	TTM —	FY 2025 12/31/2025	FY 2024 12/31/2024	FY 2023 12/31/2023	FY 2022 12/31/2022	FY 2021 12/31/2021	FY 2020 12/31/2020	FY 2019 12/31/2019	FY 2018 12/31/2018
Total Revenue	79	75	29	38	485	375	233	12	9
Cost of Goods Sold Incl. D&A	17	29	0	0	66	46	27	0	0
Gross Profit	63	46	29	38	419	330	206	12	9
Selling, General and Administrative Excl. Other	73	77	85	75	67	49	16	4	3
Research and Development	191	187	167	176	108	62	29	10	6
Other Operating Expense	11	-1	92	24	27	14	5	2	1
Operating Income	-213	-217	-315	-237	217	204	156	-4	-1
Interest Expense	0	0	0	0	4	5	7	0	0
Unusual Expense	—	—	—	—	—	—	—	—	—
Non-Operating Income (Expense)	38	40	114	63	27	20	8	2	1
Net Income Before Taxes	-174	-178	-200	-174	239	219	158	-2	0
Income Taxes	-31	-31	-38	-28	81	66	39	0	0
Consolidated Net Income	-144	-146	-163	-146	159	153	119	-2	0
Net Income From Continuing Operations	-144	-146	-163	-146	159	153	119	-2	0
Net Income	-144	-146	-163	-146	159	153	119	-2	0
EPS (Recurring)	-0.48	-0.49	-0.55	-0.51	0.56	0.56	0.32	-0.01	0.00
EPS (Basic, Before Extraordinaries)	-0.48	-0.49	-0.55	-0.51	0.56	0.56	0.32	-0.01	0.00
EPS (Diluted)	-0.48	-0.49	-0.55	-0.51	0.50	0.48	0.45	-0.01	0.00
EBITDA	-158	-149	-204	-192	260	239	170	0	1
Other After Tax Adjustments	—	—	—	—	—	—	—	—	—
Stock Option Compensation Expense	—	—	—	—	—	—	—	—	—
Price To Earnings Ratio	—	—	—	—	20.26	29.79	89.42	—	—
Price To Sales Ratio	23.36	13.63	29.70	43.43	5.95	10.52	46.28	—	—
Gross Margin	79.75	61.33	100.00	100.00	86.39	88.00	88.41	100.00	100.00
Operating Margin	-269.62	-289.33	-1,086.21	-623.68	44.74	54.40	66.95	-33.33	-11.11
Net Margin	-182.28	-194.67	-562.07	-384.21	32.78	40.80	51.07	-16.67	0.00
Shares Outstanding	303	299	294	289	285	276	268	215	151
Market Capitalization	1,845	1,023	861	1,650	2,887	3,947	10,784	—	—
Operating Lease Expense	—	—	—	—	—	—	—	—	—

Unlock full historical data

See years of past statements with Premium.

Unlock with Premium

Insider Trading Volume

Insider Trading

Insider	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Montalbano John S.	Director	May 14 '26	Buy	4.77	20,000	95,400	241,000	May 18
Thermopylae Holdings Ltd.	10% Owner	Feb 27 '26	Buy	3.44	38,000	130,720	56,134,097	Mar 02
Booth Andrew	Chief Financial Officer	Feb 27 '26	Buy	3.42	42,600	145,692	195,600	Feb 27
Thermopylae Holdings Ltd.	10% Owner	Feb 26 '26	Buy	3.27	177,457	580,284	56,096,097	Feb 27
Montalbano John S.	Director	Nov 26 '25	Buy	3.57	50,000	178,460	221,000	Nov 26
Thermopylae Holdings Ltd.	10% Owner	Mar 11 '25	Buy	2.16	343,631	742,243	56,143,640	Mar 11
Montalbano John S.	Director	Mar 10 '25	Buy	2.30	25,000	57,500	171,000	Mar 10
Montalbano John S.	Director	Mar 06 '25	Buy	2.34	60,000	140,568	146,000	Mar 07
Hansen Carl L. G.	Chief Executive Officer	Nov 25 '24	Option Exercise	2.70	56,125	151,538	898,000	Nov 26
Hansen Carl L. G.	Chief Executive Officer	Sep 20 '24	Option Exercise	2.70	56,125	151,538	841,875	Sep 24
Thermopylae Holdings Ltd.	10% Owner	Aug 29 '24	Buy	2.61	283,516	739,977	56,086,009	Aug 29
Lecault Veronique	Chief Operating Officer	Jun 21 '24	Option Exercise	0.19	83,334	15,667	2,123,456	Jun 24
Hansen Carl L. G.	Chief Executive Officer	May 31 '24	Option Exercise	2.70	56,125	151,538	785,750	Jun 03
Hansen Carl L. G.	Chief Executive Officer	Feb 26 '24	Option Exercise	2.70	56,125	151,538	729,625	Feb 27
Hansen Carl L. G.	Chief Executive Officer	Nov 23 '23	Option Exercise	2.70	56,125	151,538	673,500	Nov 27

open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR

QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.